image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.83
-4.24 %
$ 5.09 M
Market Cap
-0.24
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one AMIX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.83 USD, Autonomix Medical, Inc. Common Stock is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one AMIX stock under the base case scenario is HIDDEN Compared to the current market price of 1.83 USD, Autonomix Medical, Inc. Common Stock is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one AMIX stock under the best case scenario is HIDDEN Compared to the current market price of 1.83 USD, Autonomix Medical, Inc. Common Stock is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AMIX

image
$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
0 REVENUE
0.00%
-11.6 M OPERATING INCOME
-55.04%
-15.4 M NET INCOME
-674.99%
-6.65 M OPERATING CASH FLOW
-258.50%
-19 K INVESTING CASH FLOW
0.00%
14.4 M FINANCING CASH FLOW
2034.81%
0 REVENUE
0.00%
-3.25 M OPERATING INCOME
-18.38%
-2.71 M NET INCOME
3.35%
-2.3 M OPERATING CASH FLOW
-44.17%
-5 K INVESTING CASH FLOW
0.00%
8.97 M FINANCING CASH FLOW
0.00%
Balance Sheet Autonomix Medical, Inc. Common Stock
image
Current Assets 9.39 M
Cash & Short-Term Investments 8.61 M
Receivables 0
Other Current Assets 783 K
Non-Current Assets 16 K
Long-Term Investments 0
PP&E 16 K
Other Non-Current Assets 0
91.51 %8.32 %Total Assets$9.4m
Current Liabilities 777 K
Accounts Payable 492 K
Short-Term Debt 0
Other Current Liabilities 285 K
Non-Current Liabilities 1 M
Long-Term Debt 1 M
Other Non-Current Liabilities 0
27.66 %16.02 %56.32 %Total Liabilities$1.8m
EFFICIENCY
Earnings Waterfall Autonomix Medical, Inc. Common Stock
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 11.6 M
Operating Income -11.6 M
Other Expenses 3.84 M
Net Income -15.4 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)000(12m)(12m)(4m)(15m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Autonomix Medical, Inc. Common Stock
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)Apr '22Apr '22Jul '22Jul '22Sep '22Sep '22Dec '22Dec '22Mar '23Mar '23Jun '23Jun '23Sep '23Sep '23Dec '23Dec '23Mar '24Mar '24
Net Income -15.4 M
Depreciation & Amortization 81 K
Capital Expenditures -19 K
Stock-Based Compensation 618
Change in Working Capital 79 K
Others 8.38 M
Free Cash Flow -6.67 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Autonomix Medical, Inc. Common Stock
image
AMIX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Autonomix Medical, Inc. Common Stock
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases globenewswire.com - 1 week ago
Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, elaborates on the Company's recently announced planned follow-on market expansion study phase (“PoC 2”) of its proof-of-concept trial. globenewswire.com - 3 weeks ago
Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. “We're executing on a bold vision to expand the reach of our technology beyond pancreatic cancer pain and into a broader range of high-need visceral cancer indications,” said Brad Hauser, CEO of Autonomix. globenewswire.com - 4 weeks ago
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology Patent supports the Company's broader mission to advance minimally invasive, nerve-focused treatments across high-need indications globenewswire.com - 1 month ago
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain  Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix's strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical trial site for the follow-on phase to its proof-of-concept human clinical trial (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. The Company is on track to commence enrollment in June 2025. globenewswire.com - 1 month ago
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech Autonomix Medical, Inc.  AMIX recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management. zacks.com - 2 months ago
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology Patent strengthens Autonomix's intellectual property position in the nerve-mapping and denervation space, supporting the Company's broader mission to advance minimally invasive, nerve-focused therapeutics globenewswire.com - 2 months ago
Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event Live webcast followed by an interactive Q&A session on Thursday, May 22 nd at 4:00 PM ET globenewswire.com - 2 months ago
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here globenewswire.com - 2 months ago
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care globenewswire.com - 2 months ago
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated globenewswire.com - 2 months ago
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain Initial trial phase (“PoC 1”) achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73% of responders remaining opioid free at 4-6 week follow-up Company has initiated market expansion study (“PoC 2”) of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025 Additional indications potentially double the addressable market beyond pancreatic cancer pain THE WOODLANDS, TX, April 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided an update on the initial trial phase of its first-in-human proof-of-concept trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain. The Company enrolled twenty (20) patients in PoC 1, including the first five (5) “lead-in” patients. globenewswire.com - 2 months ago
8. Profile Summary

Autonomix Medical, Inc. Common Stock AMIX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 5.09 M
Dividend Yield 0.00%
Description Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
Contact 21 Waterway Avenue, The Woodlands, 77380 https://autonomix.com
IPO Date Jan. 29, 2024
Employees 5
Officers Mr. Landy Toth Co-Founder & Chief Technology Officer Mr. Bradley Hauser Chief Executive Officer & President Dr. Robert Schwartz M.D. Co-Founder & Chief Medical Officer Mr. Trent N. Smith CPA Chief Financial Officer Ms. Jennifer Cook Chief Business Officer